Toronto, Ontario--(Newsfile Corp. - September 13, 2013) - Gemoscan Canada, Inc. (TSXV: GES) ("Gemoscan" or the "Company"), a leading owner and marketer of food sensitivity and dietary management solutions, announces that it has retained Questrade, Inc. ("Questrade"), effective September 12, 2013, to provide market-making services in accordance with TSX Venture Exchange guidelines. The term of the agreement is twelve months, beginning September 12, 2013, at a cost of Cdn.$5,500 per month. Either party may terminate the agreement with 30 days written notice. Though Gemoscan and Questrade are unrelated and unaffiliated entities and Questrade will not receive shares or options of the Company as compensation, Questrade and its clients have or may have a direct interest in the securities of the Company.
About Questrade, Inc.
Questrade provides Canadians with high-speed, direct-access trading in the U.S. and Canadian stock and options markets through its IQ trading platforms. Questrade offers market-making services on behalf of TSX and TSX Venture Exchange listed companies providing liquidity on the stock exchange for shareholders.
About Gemoscan Canada, Inc.
Gemoscan is an industry leader in food intolerance management and maintains a first-to- market position with Canada wide distribution through select retail partners. Founded in 2003, using its proprietary patented technology, Gemoscan develops, owns and markets comprehensive food sensitivity and dietary management solutions for consumers, including the HEMOCODE™ Food Intolerance System and the MenuWise™ Food Intolerance Plan, personalized naturopathically supervised nutritional programs that promote well-being. Gemoscan is the first and only provider to commercialize a food intolerance management solution directly to consumers in partnership with retailers, and today offers the most comprehensive services available.
Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock Exchanges under the symbol 1GE.
Forward-Looking Information
This news release contains certain "forward-looking information". All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward - looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward- looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward -looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward - looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information please contact:
Company:
Brian Kalish
Chief Executive Officer
Gemoscan Canada, Inc.
416.650.1200
bkalish@hemocode.com
www.gemoscan.com